Effects of sublingual immunotherapy for dust mite on Th 17 / Treg cells in children with asthma

Li, F., Wang, X., Yin, L. et al.  Allergy Asthma Clin Immunol (2026). https://doi.org/10.1186/s13223-026-01010-8

Abstract

Objective

Observing the clinical effects of dust mite sublingual immunotherapy (SLIT) on children with asthma, changes of Th17 / Treg cells and related cytokines in order to investigate the possible pathological mechanism of immune tolerance induced by SLIT.

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials

Langley JM, Sadarangani M, Ockenhouse C et al.  Vaccine. 2026 Jan 22;75:128236. doi: 10.1016/j.vaccine.2026.128236.

Abstract

Background

Pneumococcus causes substantial morbidity and mortality worldwide in children under 5. IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine (PCV25) designed to prevent invasive pneumococcal disease from the serotypes predominant in children, particularly in low and middle income countries (LMICs).

Methods

Pneumococcal serotypes in IVT PCV25 and PCVs licensed in children.

We completed 2 randomised, parallel-group, double-blind clinical trials in Canada to evaluate the safety and immunogenicity of a single IM dose of PCV25 in healthy adults who had no history of pneumococcal vaccination or microbiologically confirmed IPD. PCV20 (Prevnar 20) was the control. In CVIA 096, 30 participants per group were randomised to PCV25 at a dose similar to PCV 20 (2.2 μg for each serotype polysaccharide (except 4.4 μg for serotype 6B) with 125 μg aluminium as aluminium phosphate (2.2/125)) or PCV20.

Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world

Davis-Lorton, M., Tachdjian, R., Lopez-Gonzalez, L. et al. Allergy Asthma Clin Immunol (2026). https://doi.org/10.1186/s13223-025-01005-x

Abstract

Background

Hereditary angioedema (HAE) causes recurring swelling attacks, leading to substantial disease burden. This real-world, retrospective study aimed to evaluate HAE attack rates before and after berotralstat initiation stratified by patients’ baseline attack frequency.

Methods

Specialty Pharmacy data from Optime Care, Inc. (12/2020–01/2024), the sole berotralstat dispenser in the United States, were analyzed. Eligible patients had  ≥ 2 berotralstat dispensings (first =  index) and ≥ 1 self-assessment of attacks at baseline (90-days pre-index) and follow-up (first-to-last dispensing). Patients were classified by HAE type (based on laboratory measurements) and baseline attacks (≥ 5, 2–4, 1, and 0 attacks/month). Follow-up attack rates were compared with baseline using mean differences, confidence intervals, and P-values. Among those with 0 baseline attacks/month, proportions with 0 follow-up attacks/month were assessed.

Results

Of 390 eligible patients with HAE with C1 esterase inhibitor (C1INH) deficiency (HAE-C1INH) and 311 with HAE with normal C1INH (HAE-nC1INH), most were female (64.1% and 77.5%) with mean ages of 39.3 and 48.1 years, respectively.

Patient perspectives of allergic rhinitis and allergen immunotherapy: A qualitative study

Jacob J, Joyce C, Lloyd M et al. J Allergy Clin Immunol Glob. 2025 Dec 1;5(2):100621. doi: 10.1016/j.jacig.2025.100621.

Abstract
Background
Allergic rhinitis (AR) is a highly prevalent condition associated with significant morbidity globally. Few recent studies have detailed the experiences of sufferers and explored their perspectives of treatment options. Allergen immunotherapy (AIT) is an effective treatment option that remains underused in eligible patient populations.
Objective
We sought to describe patient perspectives of AR and treatment options including AIT.
Methods
Twenty-five semistructured interviews were conducted with adult participants at a tertiary hospital center in Sydney, Australia. Authors used an inductive thematic analysis methodology to code and interpret the data.
Results
Three major themes emerged from the qualitative thematic analysis: (1) a prolonged journey with symptoms, (2) multiple trials of therapy with incomplete symptom control, and (3) diverse experiences with AIT.

Survey: Knowledge, attitudes, perceptions, barriers, and pattern of use of oscillometry in Asthma: survey based, cross-sectional study

Dear Healthcare Professional,

Impulse (IOS) or forced (FOT) oscillometry is an advanced technique for assessing pulmonary function. It measures respiratory impedance by applying low-amplitude oscillatory signals to the airway during spontaneous breathing.

Its ability to characterize the mechanics of the distal airways and detect abnormalities that may not be evident with conventional tests makes it a valuable complementary tool for monitoring and stratifying the severity of asthma.

This survey is completely anonymous and aims to optimize the implementation of oscillometry in the assessment and monitoring of patients with asthma.

KAPA Oscillometry Survey English version: https://ccherrezo.questionpro.com/t/AaVIxZ7gPp

KAPA Oscillometry Survey Spanish version: https://ccherrezo.questionpro.com/t/AaVIxZ7iUs

Chronic rhinosinusitis with and without nasal polyps: the state-of-the-art of current treatment strategies and future developments

Nappi E, Marzio V, Giombi F et al.  Front Allergy. 2025 Dec 15;6:1714577. doi: 10.3389/falgy.2025.1714577.

Abstract

Therapeutic evolution in primary chronic rhinosinusitis (CRS):
from symptomatic relief to targeted inflammatory modulation 

Over the past decade, chronic rhinosinusitis (CRS) management has undergone substantial transformation, shifting from conventional symptom-focused treatments to precision medicine strategies grounded on molecular insights. The introduction of biologic agents has significantly changed the therapeutic landscape for CRS with nasal polyps (CRSwNP), directly addressing key inflammatory pathways and leading to marked reductions in nasal polyp burden, overall disease impact, and corticosteroid use.

A strategic framework for digital and sustainable transformation in allergy care: An EAACI position paper

Feketea G, Paciência I, Chang YS et al. Pediatr Allergy Immunol. 2026 Jan;37(1):e70270. doi: 10.1111/pai.70270. 

Abstract

Background

Allergic diseases, particularly in children, are increasing worldwide and impose growing clinical, economic, and environmental burdens on healthcare systems. Conventional models of allergy care face limitations in early diagnosis, long-term disease monitoring, patient engagement, and sustainability, highlighting the need for innovative and scalable solutions.

Objectives

This position paper aims to propose a global framework for integrating digital health innovations with sustainable models of allergy and immunology care, with particular attention to pediatric and general allergy services.

Methods

The paper is formulated as an expert opinion–based position document informed by current scientific evidence on digital health applications and sustainable healthcare practices in allergy and immunology. Key domains were identified through literature review and consensus discussions, focusing on digital transformation, environmental sustainability, and international collaboration.

Results

The proposed roadmap highlights three strategic priorities: (1) leveraging digital health solutions—including mobile health, telemedicine, and artificial intelligence—to enhance early diagnosis, personalized treatment, and real-time disease monitoring; (2) embedding environmentally sustainable practices into routine allergy care to reduce healthcare-related carbon emissions; and (3) fostering international collaboration among clinicians, researchers, and policymakers to promote equitable access to digital allergy care across diverse healthcare systems.

Biologic Therapies: A Systematic Review of the Indications, Efficacy, Safety, and Outcomes in Ear, Nose, and Throat Diseases

Al Saloom Z, Alawainati M, Abdeen Z, et al. (January 07, 2026)  Cureus 18(1): e101059. doi:10.7759/cureus.101059

Abstract

Biologic therapies, such as omalizumab, mepolizumab, and dupilumab, are novel therapeutic agents that offer a targeted approach for managing chronic inflammatory and immune-mediated ear, nose, and throat (ENT) conditions. However, the indications, efficacy, and adverse events of these medications in various ENT disorders have not been studied before. Therefore, this systematic review was performed to evaluate their indications, clinical efficacy, and safety in ENT management. A systematic search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines across five major databases: